BioSpace News Archive

CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that CEO Yehiel Tal will moderate the International Society for Biofabrication’s (ISBF) virtual event on May 2nd. Mr. Tal also serves as a board member of ISBF.

Lyra Therapeutics, Inc. today announced that the first patient was treated in the Part Part 1/non-randomized portion of the Phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery.

Axsome to host conference call and webcast on Monday, May 2, 2022 at 8:00 AM Eastern Time.

Ardelyx, Inc. today announced that the Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA), has provided an interim response to Ardelyx’s second level of appeal of the Complete Response Letter (CRL) received on July 28, 2021, for XPHOZAH.

Silence Therapeutics plc today announced that it will receive a $2.0 million cash payment from Hansoh Pharmaceutical Group Company Limited (“Hansoh”) following the achievement of an undisclosed preclinical milestone.

NeoGenomics, Inc. announced today that they are partnering with Eli Lilly and Company on a sponsored testing program for eligible patients with metastatic non-small cell lung cancer (NSCLC) at no cost.

Enzolytics, Inc. (OTC PINK:ENZC) ( https://enzolytics.com/ ). Enzolytics continues to make significant progress in its multiple therapeutic platforms and outlines here the technical aspects of the implementation of those programs and the Company’s plans for the future.

PolyPid Ltd. announced today that the Company will present clinical data at the 13th European and Global CLINAM Summit for Nanomedicine, being held virtually on May 2–4, 2022.

Lineage Cell Therapeutics, Inc. today announced a new cell therapy development program: photoreceptor neural cell (PNC) transplants for the treatment of vision loss due to photoreceptor dysfunction or damage.

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), today announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology.